IL13RA2 and glioblastoma: Moreover, Pep-1-conjugated nanoparticles and the α-particle emitter Actinium-225 have recently been shown to target IL-13Rα2-overexpressing GBM, indicating the peptide’s potential in drug-targeting GBM [43,44].